
A menudo diagnosticada en la niñez o adolescencia, la RP es una enfermedad retiniana hereditaria que causa una pérdida progresiva de la visión nocturna y periférica. La condición a menudo conlleva a una ceguera legal y a veces completa.
Podcasts
-
Eye on the Cure Podcast | Episode 92: Lance Baldo, MD
Lance Baldo, MD, CEO at Beacon Therapeutics, is discussing his company’s gene therapy for XLRP.
-
Eye on the Cure Podcast | Episode 91: Dr. George Magrath
Dr. George Magrath is the CEO of Opus Genetics, a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases.
-
Eye on the Cure Podcast | Episode 88: Richard Small
Richard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTO™, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Dr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
Eye on the Cure Podcast | Episode 76: The Lemay-Pelletier Family
When the Lemay-Pelletier family from Montreal learned that three of their four children were losing vision from retinitis pigmentosa, they made the bold decision to spend 15 months traveling the world to give their kids as many visual memories as possible.
-
Eye on the Cure Podcast | Episode 70: Karen Petrou
Karen Petrou, the new board chair at the Foundation, talks to host Ben Shaberman about her vision for the Foundation moving forward. Karen has been an active director on the Foundation’s board for nearly two decades. She is co-founder and managing partner of Federal Financial Analytics, a firm providing analytical and advisory services on legislative, regulatory, and public-policy issues affecting financial services companies. Karen has RP and lives in Washington, DC, with her guide dog, Ike.